Category: Ovarian Cancer

Percentage of Progression vs Survival

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients

A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients Contact Us Summary This study describes the immune response elicited by two vaccine approaches using the wild-type (wt) p53 vaccine. The founding suggest that using either vaccination approach […]

Change in expression

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer Contact Us Summary In recurrent ovarian and breast cancer, researchers looked at the tumor response and in vivo proliferation of allogeneic NK cells.After lymphodepleting chemotherapy, adoptive transfer of haplo-identical NK cells causes transitory donor chimerism, which […]

Progress free trial

Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy

Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy Contact Us Summary Cytokine-induced killer (CIK) cells are demonstrated to hold potent cytolytic effect against ovarian cancer cells in vitro and in vivo. However, the clinical efficacy of maintenance therapy of CIK cells in patients with […]

DC-CIK-CHEMOTHERAPY

Clinical efficacy analysis of dendritic cell-cytokine induced killer cell immunotherapy combined with paclitaxel-cisplatin chemotherapy in patients with advanced ovarian cancer

Clinical efficacy analysis of dendritic cell-cytokine induced killer cell immunotherapy combined with paclitaxel-cisplatin chemotherapy in patients with advanced ovarian cancer Contact Us Summary The study aims to investigate the efficacy and safety of dendritic cellcytokine induced killer cell (DC-CIK) immunotherapy combined with paclitaxel-cisplatin chemotherapy in the treatment of patients with advanced ovarian cancer. The treatment […]

Overall Survival

Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-a and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases

Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-a and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases Contact Us Summary This study aims to demonstrate the safety and efficacy of adjuvant αDC1 vaccination with chemokine modulation (CKM) after Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) […]

Overall Survival

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers

Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers Contact Us Summary This study investigates the correlation of cytokines produced by Dendritic Cells with clinical outcomes in patients with diverse cancers. The results reveal, aDC injections were feasible and safe. Increased production of specific cytokines was correlated with […]

Overall Survival Rate

Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02)

Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02) Contact Us Summary The data aims to examine patients with platinum-sensitive ovarian cancer (SOV02) and their response to Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy. The results show that the combined treatment had a favorable safety profile in patients with platinum-sensitive […]

Change in Expression

Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial

Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial Contact Us Summary This study examines patients with Glioblastoma multiforme (GBM) and how they respond to a-type-1 Dendritic Cell vaccine. As a result a significant survival-prolonging effect was verified in DC-treated glioma patients. The vaccines have a potential therapeutic effect […]

Stages of Ovarian Cancer

Phase I/II clinical trial of modulated electro- hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer

Phase I/II clinical trial of modulated electro- hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer Contact Us Summary This study aims to determine the feasibility and efficacy of modulated electro-hyperthermia (mEHT) as a second-line therapy in progressive ovarian cancer. The power of mEHT was gradually increased from 135 W to […]